Skip to content

PP&E (Net) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$7.66B+6.2%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$23.27B+11.5%
AbbVie logo
AbbVieABBV
$5.69B+8.6%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
$70.02M-15.6%
Regenxbio logo
RegenxbioRGNX
$101.87M-11.0%
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
$1.34M-44.9%

Other financials

Income statement

See full
Operating income-$10.8M-131%
Net income-$10.1M-122%
EPS (diluted)-$0.18-20.0%

Balance sheet

See full
Cash & equivalents$79.3M+398%
Total debt$1.0M-2.0%
Total equity$84.4M+779%
Total assets$95.8M+382%

Cash flow

See full
Operating cash flow-$9.8M-483%
CapEx$32.5K-52.0%
Free cash flow-$9.9M-462%

Valuation

See full
Market cap$691.97M+1,008%
Enterprise value$613.75M+1,190%

Returns & leverage

See full
Return on equity-74.4%-18.6pp
Debt / equity-0.1×
Current ratio8.8×+7.0×

Where this comes from

Reported directly by Immix Biopharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immix Biopharma, Inc.'s pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immix Biopharma, Inc.'s PP&E (net)?
Immix Biopharma, Inc. (IMMX) reported PP&E (net) of $2.43M in Q1 2026.
How has Immix Biopharma, Inc.'s PP&E (net) changed year-over-year?
Immix Biopharma, Inc.'s PP&E (net) increased by 14.3% year-over-year, from $2.12M to $2.43M.
What is the long-term trend for Immix Biopharma, Inc.'s PP&E (net)?
Over 5 years (2020 to 2025), Immix Biopharma, Inc.'s PP&E (net) has grown at a 221.3% compound annual growth rate (CAGR), from $7.36K to $2.52M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.